Tarloxotinib
- Generic Name
- Tarloxotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H24BrClN9O3
- CAS Number
- 1636938-13-0
- Unique Ingredient Identifier
- H8768UL06V
- Background
Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Phase 2
Terminated
- Conditions
- EGFR Exon 20 Insertion MutationHER2-activating MutationERBB FusionNSCLC Stage IIIBNRG1 FusionNSCLC, Stage IVNSCLC, Stage IIICNSCLC, Recurrent
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 41
- Registration Number
- NCT03805841
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
🇺🇸University of California San Francisco, Helen Diller Cancer Center, San Francisco, California, United States
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Proacta, Incorporated
- Target Recruit Count
- 33
- Registration Number
- NCT01631279
- Locations
- 🇳🇿
Waikato Hospital, Waikato, New Zealand
🇺🇸University of California-Davis Comprehensive Cancer Ctr, Sacramento, California, United States
🇺🇸Scottsdale Healthcare, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath